Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
Date:10/31/2011

MALVERN, Pa., Oct. 31, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2011. For the third quarter of 2011, Auxilium reported net revenues of $66.7 million compared to net revenues of $53.6 million in the third quarter of 2010.  The net loss for the third quarter of 2011 was $(4.1) million, or $(0.08) per share, compared to a net loss of $(12.8) million, or $(0.27) per share, reported for the third quarter of 2010.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

"We believe that the progress we made in the third quarter of 2011 will drive long term shareholder value.  XIAFLEX® revenues showed sequential growth over the second quarter of 2011, despite a slight decrease in overall Dupuytren's procedure volumes, and new XIAFLEX data were well received by physicians attending the American Society for Surgery of the Hand meeting.  We remain encouraged by the physician and patient success stories and believe that XIAFLEX will become the standard of care for Dupuytren's contracture," said Armando Anido, Chief Executive Officer and President of Auxilium.  "Testim® continued to perform well, despite continuing competition in the testosterone replacement market, with prescriptions posting growth over the third quarter of 2010 and over the second quarter 2011."  

Third Quarter and Recent Operational Highlights: XIAFLEX:

  • Worldwide net revenues for XIAFLEX were $13.1 million for the third quarter 2011, up 130% versus the third quarter of 2010.
  • Net revenues of XIAFLEX in the U.S. were $10.3 million in the third quarter 2011, up 124% versus the third quarter of 2010.  
  • At the 2011 ASSH meeting in early September, physician attendees expresse
    '/>"/>

  • SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update
    2. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
    3. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
    4. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
    5. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
    6. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
    7. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
    8. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
    9. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
    10. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
    11. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... 28, 2015  Kerastem Technologies announce that the Company ... FDA Center For Biologics Evaluation and Research (CBER) Office ... clinical trial investigating the safety and feasibility of the ... male pattern baldness (androgenic alopecia). The phase ... clinical work in Europe and ...
    (Date:7/28/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., ... UTHR ) today announced its financial results for ... "Orenitram ®  sales grew nearly 300% as compared ... product was first launched," said Roger Jeffs, Ph.D., ... growth in Orenitram sales was due to an ...
    (Date:7/27/2015)... Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), ... treatment of cancer, today provides the following financial update. ... $1,000,000 unit offering private placement.  This financing is a ... at a price of $0.06 per unit.  Each unit ... share purchase warrant.  Each whole warrant is exercisable into ...
    (Date:7/27/2015)... July 27, 2015 Research presented at the ... expand on the studies that led to a fingerprick ... for this disease to receive approval from the World ... breaking Ebola,s grip on West Africa ... enabling healthcare workers to isolate and treat these patients ...
    Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Quest PharmaTech Closes $1,000,000 Private Placement 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
    ... Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged ... of human viral and other infectious diseases, today reported unaudited ... 31, 2008. At December 31, 2008, Idenix,s cash, cash equivalents ... , ...
    ... Audit Confirms Responsible Use. , ... Wilmington, DE (Vocus) ... have verified its plant biotechnology research and development processes are in ... its North American operations. The ETS third-party audit confirms that ...
    ... ON LICENSING, FUNDING, ACQUISITION AND INFORMATION MANAGEMENT INITIATIVES TO ACCELERATE ... Sinobiomed Inc. ("Sinobiomed," or "the Company") (OTC Bulletin Board: SOBM) ... management team to accelerate the Company,s growth. The new management ... , Dr. Anchie ...
    Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 7DuPont Biotech Stewardship Program Gains External Certification 2DuPont Biotech Stewardship Program Gains External Certification 3Sinobiomed Announces New Executive Team 2Sinobiomed Announces New Executive Team 3
    (Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
    (Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
    (Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
    Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
    ... first time, researchers have discovered a disease mechanism that links ... of ALS -- and points to a possible therapeutic target. ... in the journal Nature Neuroscience . ALS is ... and death within three to five years of diagnosis. ...
    ... ongoing concern about plastic waste accumulating in municipal landfills, ... are reporting development of a new ultra-light biodegradable foam ... in milk and ordinary clay. The new substance could ... products, they report in the ACS, Biomacromolecules , ...
    ... ever on the verge of suicide, requiring the close ... cells from pulling the trigger. This self-destructive tendency can ... cells are permitted to kill themselves, but it can ... memories, for instance. Rockefeller University scientists are parsing this ...
    Cached Biology News:Link between 2 forms of ALS suggests drug target 2Link between 2 forms of ALS suggests drug target 3'Reaper' protein strikes at mitochondria to kill cells 2
    SRY (sex determining region Y)-box 10...
    Complement C1r [Human]...
    biotin-4-fluorescein...
    ... LVF-CUV-ADP, FHS-LVF and CVD-Diffuse We've combined ... Filters to create the world's first notch ... adjustable bandpass. Each filter features an excellent ... These filters -- with interference coatings ...
    Biology Products: